Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01735032
Other study ID # 2011-703
Secondary ID
Status Recruiting
Phase N/A
First received October 22, 2012
Last updated November 29, 2012
Start date October 2012
Est. completion date May 2016

Study information

Verified date October 2012
Source Hospices Civils de Lyon
Contact Julien Jung, Dr.
Phone 0033 472 117 833
Email julien.jung@chu-lyon.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Observational

Clinical Trial Summary

Epilepsy is the most common chronic neurological disorder in the world, affecting more than 50 million people worldwide. Approximately 35% of patients with epilepsy are refractory to all available antiepileptic drugs. Drug-resistant epilepsies are often partial or focal. Patients with drug-resistant focal epilepsy suffer from an increased risk of death, primarily due to seizure-related fatalities, in comparison with the general population. The only therapeutic option for this form of epilepsy is the surgical removal of the region of the brain responsible for seizures, called the epileptogenic zone (EZ). This requires the precise localization of the EZ based on a comprehensive pre-surgical evaluation of patients.

Today the gold standard for localizing the EZ and validating a non-invasive technique for localization of the EZ remains intracerebral stereo-EEG (stereo-electroencephalography or SEEG) recordings of spontaneous seizures. The implementation strategy of the intracerebral depth electrodes is guided by clinical and neuroimaging data, including anatomical Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) with FDG (fluoro-Deoxy-Glucose) and MagnetoEncephaloGraphy (MEG). Although the contribution of each technique in the pre-surgical localization of the EZ has already been shown, no wide-scale study has examined the cumulative contribution of these three techniques.


Description:

The purpose of this study is (i) to evaluate rigorously the diagnostic value of multimodal imaging for non-invasive localization of the EZ and (ii) to better target the indications for intracerebral recordings (SEEG).


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date May 2016
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patient with drug-resistant focal epilepsy

- Candidates for pre-surgical evaluation including FDG PET, MRI, MEG and SEEG recordings.

- Age 18-65 years

- EEG-confirmed focal epilepsy for >2 years

- Signed informed consent form.

Exclusion Criteria:

- Age <18 years and >65 years

- Contraindication to the MRI

- Pregnant woman

- Head size incompatible with MEG recordings

- Adult subject to legal protection measure.

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
France Hospices Civils de Lyon Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Localizing value of MEG, FDG-PET and MRI for the determination of the Epileptogenic Zone defined by SEEG recordings Pathological volumes defined by multimodal imaging (MEG, FDG-PET and MRI) will be compared to the topography of the EZ defined by SEEG recordings.
For each patient, we will sum the total number of intracerebral depth electrodes included in the EZ. Then, for each functional volume obtained from multimodal data fusion, we will count the total number of electrodes in the latter (Vol elec_tot) and the number of electrodes included in the EZ (Vol elec_ze).
180 days No
Secondary sensitivity and specificity For each functional volume, two parameters will be defined: sensitivity and specificity. These parameters will be calculated as follows: sensitivity = (Vol elec_ze) / (Pat elec_ze) and specificity = (Vol elec_ze) / (Vol elec_tot). 180 days No
See also
  Status Clinical Trial Phase
Withdrawn NCT00982787 - Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy Phase 2
Completed NCT00898560 - Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive Phase 1
Completed NCT01090934 - Localizing the Epileptogenic Zone With High Resolution Electroencephalography N/A
Terminated NCT00391534 - EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy Phase 3
Terminated NCT01496612 - Buspirone Therapy for Localized Epilepsy Phase 2
Completed NCT00900237 - Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine Phase 1
Recruiting NCT04903314 - Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures Phase 1
Completed NCT01373190 - Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy N/A
Completed NCT00894478 - Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging N/A
Recruiting NCT03478852 - Investigating Epilepsy: Screening and Evaluation
Recruiting NCT01273129 - Surgery as a Treatment for Medically Intractable Epilepsy
Completed NCT00001666 - Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy N/A
Completed NCT00001932 - Serotonin Receptors in Seizure Disorders N/A
Completed NCT00908349 - Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy Phase 3
Completed NCT02076698 - Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy Phase 3
Completed NCT00706160 - Language Mapping in Patients With Epilepsy
Completed NCT01397968 - Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures Phase 2
Completed NCT01866111 - A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures Phase 2
Completed NCT00957047 - Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy Phase 3
Terminated NCT01281956 - PRX-00023 Therapy in Localization-Related Epilepsy Phase 2